Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
Status:
Terminated
Trial end date:
2018-01-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751
in Parkinson's disease patients at early stage of the disease.